安进Amgen Inc. (AMGN) 2019年年度报告「NASDAQ」.pdf

1、2019 Letter to Shareholders|AmgenLETTER TO SHAREHOLDERSRobert A.Bradway,Chairman and Chief Executive Officer,Amgen Inc.To My Fellow Shareholders:As I write this letter,Amgen is approaching a significant milestone:our 40th anniversary.The date was April 8,1980,when our founders established Applied Mo

2、lecular Genetics(later shortened to Amgen)in Thousand Oaks,California,to explore new business opportunities made possible by the biotechnology revolution getting underway at that time.Since then,weve seen hundreds of biotech companies come and go as Amgen flourished.While Thousand Oaks still serves

3、as our global headquartersand our original building still standsAmgen ranks today among the largest companies on the Fortune 500,with more than 23,000 employees in 100 countries around the world.We are proud of what we have accomplishedand eager to do more.We know that an aging global population wil

4、l require innovative new treatments for illnesses like cancer and heart disease that claim millions of lives and cost society hundreds of billions of dollars each year.The pioneering spirit of Amgen a hallmark for four decadesgives us confidence that we can play an increasingly important role in the

5、 global healthcare ecosystem.By doing so,we are also confident that we can continue to deliver on the commitments that we make to you,our shareholders.DELIVERING RESULTSAs anticipated,total revenues decreased slightly in 2019 as double-digit,volume-driven growth of many of our newer medicines did no

6、t fully offset the decline in sales of our off-patent legacy products,which faced increased competition around the world.Total revenues of$23.4 billion were down 2%from the prior year,with non-GAAP earnings per share rising 3%to a record$14.82.1 For the full year,Amgen achieved a non-GAAP operating